The timing of hormone therapy in patients with advanced prostate cancer remains controversial. Although evidence from the Veterans Administration Cooperative Urological Group (VACURG) data indicated the potential benefit of immediate hormone treatment in terms of time to progression and disease-specific survival, it also supported the possibility of deferred treatment. This review looks at the results of subsequent studies of immediate versus deferred hormone therapy including the Medical Research Council (MRC) study, the European Organisation for Research and Treatment of Cancer (EORTC) studies, the Radiation Therapy Oncology Group (RTOG) study and the Eastern Cooperative Oncology Group (ECOG) study. Data from these studies and the availability of newer, better tolerated hormone therapies may well mean that the survival and welfare of patients with advanced prostate cancer could be considerably better with immediate hormone therapy rather than deferred treatment.

Keywords:
Prostate cancer, Hormone therapy, Immediate treatment
1.
Byar DP: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973;32:1126–1130.
2.
Byar DP, Corle DK: Hormone therapy for prostate cancer. Results of the Veterans Administration Co-operative Urological Research Group Study; in: Consensus Development Conference in the Management of Clinically Localised Prostate Cancer. Bethesda, NCI, 1988, vol 7, p 165.
3.
The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 1997;79:235–246.
4.
Kirk D: MRC study: When to commence treatment in advanced prostate cancer. Prost Cancer Prost Dis 1997;1:11–15.
5.
Kirk D, on behalf of the MRC Prostate Cancer Working Party: Does hormonal treatment for prostate cancer cause excess deaths: Data from the MRC immediate vs. deferred hormone treatment study. BJU Int 1999;83(suppl 4):9 (abs 71).
6.
Van den Ouden D, Tribukait B, Blom JHM, Fossa SD, Kurth KH, Ten Kate FJW, Heiden T, Wang N, Schröder FH, and The European Organization for Research and Treatment of Cancer Genitourinary Group: Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph notes of prostate cancer patients: Impact on time to progression. J Urol 1993;150:400–406.
7.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
8.
Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Grignon D, Caplan R, Cox JD: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616–623.
9.
Pilepich MV, Winter K, Roach M, Russell AH, Sause W, Rubin P, Byhardt R, Machtay M, Grignon D: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced prostatic carcinoma. Proc ASCO 1998;17:308a (abs 1185).
10.
Zincke H, Utz DC, Thule PM, Taylor WF: Treatment options for patients with stage D1 (T0–3, N1–2, M0) adenocarcinoma of prostate. Urology 1987;4:307–315.
11.
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781–1788.
12.
George N: Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1988;1:494–497.
13.
Steinberg GD, Bales GT, Brendeler CB: An analysis of watchful waiting for clinically localised prostate cancer. J Urol 1998;159:1431–1436.
14.
Adolfsson J, Rönström L, Carstensen J, Lowhagen T, Hedlund PO: The natural course of low stage, low grade prostatic carcinoma. Br J Urol 1990;65:611–614.
15.
George N: Therapeutic dilemmas in prostate cancer: Justification for watchful waiting. Eur Urol 1998;34(suppl 3):33–36.
16.
Iversen P: Quality of life issues relating to endocrine treatment options. Eur Urol 1999;36(suppl 2):20–26.
© 2001 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.